878
Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.
 patients: Subject; a hematologic malignancy: Effect; several years after intravesical chemotherapy: Treatment; with etoglucid, doxorubicin, and mitomycin C.: Treatment; etoglucid: Treatment.Drug; doxorubicin: Treatment.Drug; mitomycin C.: Treatment.Drug; superficial bladder cancer: Treatment.Disorder; several years after: Treatment.Time_elapsed; intravesical: Treatment.Route; mitomycin C.: Combination.Drug; doxorubicin: Combination.Drug; etoglucid: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients: Subject; a hematologic malignancy: Effect; several years after intravesical chemotherapy: Treatment; with etoglucid, doxorubicin, and mitomycin C.: Treatment; etoglucid: Treatment.Drug; doxorubicin: Treatment.Drug; mitomycin C.: Treatment.Drug; superficial bladder cancer: Treatment.Disorder; several years after: Treatment.Time_elapsed; intravesical: Treatment.Route; mitomycin C.: Combination.Drug; doxorubicin: Combination.Drug; etoglucid: Combination.Drug